Hepatology:评估肝癌预后的新因子!

2017-11-12 MedSci MedSci原创

Hippo通路可以调节细胞的分化、增殖和凋亡。激活Hippo通路后,它可以抑制转录激活物YAP进入细胞核,从而抑制促增殖基因的转录。因此,动态和精确的控制Hippo途径对器官大小的控制和肿瘤形成的预防至关重要。 Hippo信号由越来越多的上游调控因子(包括WWC蛋白)控制,这些蛋白可以触发丝氨酸/苏氨酸激酶途径。其中的一个组成部分是LATS激酶,其可以将YAP磷酸化,并将其捕获在细胞质中

Hippo通路可以调节细胞的分化、增殖和凋亡。激活Hippo通路后,它可以抑制转录激活物YAP进入细胞核,从而抑制促增殖基因的转录。因此,动态和精确的控制Hippo途径对器官大小的控制和肿瘤形成的预防至关重要。 


Hippo信号由越来越多的上游调控因子(包括WWC蛋白)控制,这些蛋白可以触发丝氨酸/苏氨酸激酶途径。其中的一个组成部分是LATS激酶,其可以将YAP磷酸化,并将其捕获在细胞质中。

已有研究显示,WWC蛋白在体外与LATS相互作用并刺激其激酶活性,从而直接促进磷酸化YAP的细胞质积累。然而,WWC蛋白在调节细胞增殖,控制器官大小和预防体内肿瘤中的功能尚未确定。

近期,一项发表在杂志Hepatology上的研究显示,在小鼠肝脏WWC表达的缺失可以导致组织的过度生长、炎症、纤维化和肝癌的形成。WWC缺陷的小鼠肝脏显示出LATS活性的降低,YAP介导的基因转录增加和肝祖细胞增殖的增强。另外,肝脏中WWC表达的缺失也加速了血管生成抑制素结合蛋白(其作为YAP活性的负调节剂)的转换。

此项研究结果表明:WWC蛋白可以作为肝细胞生长和肝肿瘤发生中经典和非经典Hippo信号传导调节剂的基本功能。因此,WWC蛋白的表达可以作为人类肝癌预后的新因子。

原始出处:
Hermann A, Wennmann DO, et al. WWC proteins regulate hepatic cell differentiation and tumorigenesis via the Hippo signaling pathway. Hepatology. 2017 Nov 8. doi: 10.1002/hep.29647. 

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=263551, encodeId=e207263551f7, content=好好学习努力向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Nov 23 08:46:05 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262456, encodeId=6d6d262456c6, content=评估肝癌预后的新因子., beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Nov 19 07:32:19 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262041, encodeId=9abb262041c2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Nov 17 16:55:06 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426888, encodeId=8f761426888db, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Nov 14 04:09:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260829, encodeId=46d026082937, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Nov 12 19:15:17 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260793, encodeId=dbff260e93ca, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Nov 12 14:28:41 CST 2017, time=2017-11-12, status=1, ipAttribution=)]
    2017-11-23 虈亣靌

    好好学习努力向上

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=263551, encodeId=e207263551f7, content=好好学习努力向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Nov 23 08:46:05 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262456, encodeId=6d6d262456c6, content=评估肝癌预后的新因子., beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Nov 19 07:32:19 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262041, encodeId=9abb262041c2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Nov 17 16:55:06 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426888, encodeId=8f761426888db, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Nov 14 04:09:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260829, encodeId=46d026082937, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Nov 12 19:15:17 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260793, encodeId=dbff260e93ca, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Nov 12 14:28:41 CST 2017, time=2017-11-12, status=1, ipAttribution=)]
    2017-11-19 jyzxjiangqin

    评估肝癌预后的新因子.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=263551, encodeId=e207263551f7, content=好好学习努力向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Nov 23 08:46:05 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262456, encodeId=6d6d262456c6, content=评估肝癌预后的新因子., beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Nov 19 07:32:19 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262041, encodeId=9abb262041c2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Nov 17 16:55:06 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426888, encodeId=8f761426888db, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Nov 14 04:09:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260829, encodeId=46d026082937, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Nov 12 19:15:17 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260793, encodeId=dbff260e93ca, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Nov 12 14:28:41 CST 2017, time=2017-11-12, status=1, ipAttribution=)]
    2017-11-17 虈亣靌

    好消息.值得学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=263551, encodeId=e207263551f7, content=好好学习努力向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Nov 23 08:46:05 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262456, encodeId=6d6d262456c6, content=评估肝癌预后的新因子., beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Nov 19 07:32:19 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262041, encodeId=9abb262041c2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Nov 17 16:55:06 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426888, encodeId=8f761426888db, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Nov 14 04:09:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260829, encodeId=46d026082937, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Nov 12 19:15:17 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260793, encodeId=dbff260e93ca, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Nov 12 14:28:41 CST 2017, time=2017-11-12, status=1, ipAttribution=)]
    2017-11-14 gwc384
  5. [GetPortalCommentsPageByObjectIdResponse(id=263551, encodeId=e207263551f7, content=好好学习努力向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Nov 23 08:46:05 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262456, encodeId=6d6d262456c6, content=评估肝癌预后的新因子., beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Nov 19 07:32:19 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262041, encodeId=9abb262041c2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Nov 17 16:55:06 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426888, encodeId=8f761426888db, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Nov 14 04:09:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260829, encodeId=46d026082937, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Nov 12 19:15:17 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260793, encodeId=dbff260e93ca, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Nov 12 14:28:41 CST 2017, time=2017-11-12, status=1, ipAttribution=)]
    2017-11-12 虈亣靌

    优质资源.共同学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=263551, encodeId=e207263551f7, content=好好学习努力向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Nov 23 08:46:05 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262456, encodeId=6d6d262456c6, content=评估肝癌预后的新因子., beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Nov 19 07:32:19 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262041, encodeId=9abb262041c2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Nov 17 16:55:06 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426888, encodeId=8f761426888db, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Nov 14 04:09:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260829, encodeId=46d026082937, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Nov 12 19:15:17 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260793, encodeId=dbff260e93ca, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Nov 12 14:28:41 CST 2017, time=2017-11-12, status=1, ipAttribution=)]
    2017-11-12 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

相关资讯

J Gastroenterol Hepatol:从肝炎病毒认识肝癌风险!

根据10月24日在《J Gastroenterol Hepatol》上发表的一项研究,乙型肝炎病毒(HBV)DNA和乙型肝炎表面抗原(HBsAg)水平升高与肝癌风险增加有关。

Oncotarget:小身材的大作用——miR-148/miR-152家族的预后价值

本期为大家介绍一篇基于观察研究的系统回顾来评估miR-148/miR-152家族在癌症患者中预后价值的文章。文章发表在Oncotarget期刊上,题目为Evaluatingthe prognostic value of miR-148/152 family in cancers: based on a systemicreview of observational studies(基于观察研究的系

Radiology:射频消融对早期乏血供肝癌的疗效怎么样?

本研究旨在回顾性评价射频脉冲(RFA)对早期乏血供肝细胞肝癌(HCCs)的临床预后,并将其与典型富血供HCCs的临床预后进行比较,将结果发表在Radiology上。

Nature :慢性肝炎如何才会发展成肝癌?

已知慢性炎症驱使许多癌症,特别是肝癌。研究人员早就认为这是因为炎症直接影响癌细胞,刺激它们的分裂并保护它们免于细胞死亡。但加州大学圣地亚哥分校医学院的研究人员现在已经发现,慢性肝脏炎症还通过抑制免疫监视来促进癌症 - 这是一种被认为是免疫系统抑制癌症发展的天然防御机制。

7个肝脏边缘的肿瘤,您能诊断对几个?

肝脏边缘性肿瘤的诊断思路:定位:(1)肝脏来源(2)非肝脏来源

我国首发肝癌登记新数据,肝癌主要致病诱因是病毒性肝炎,没马兜铃酸什么事

近日,中国临床肿瘤学会年会上,由秦叔逵教授牵头的《中国原发性肝癌临床登记调查 (CLCS)》初步结果公布。结果显示,肝细胞癌(HCC)为我国原发性肝癌(PLC)最常见病理类型,男性患者居多,毒性感染和(或)饮酒是致病主因,AFP、肿瘤分期和病理学分级是HCC诊断和预后的重要指标。